virus-like particle vaccine by intranasal vaccination elicits protective immunity against 系统标签: virus syncytial intranasal viral vaccine respiratory ActaBiochimBiophysSin,2017,49(1),74–82doi:10.1093/abbs/gmw118AdvanceAccessPublicationDate:14December2016OriginalArticleOriginalArticleVirus-likeparticlevaccineby...
In certain embodiments, virus-like particles such as synthetic envelope VLPs or synthetic membrane VLPs are provided herein. In some embodiments, the VLP comprises a lipid bilayer. In some embodiments, VLPs comprise purified antigen anchored in a lipid bilayer. Some embodiments relate to vaccines ...
Shan Lu, in Vaccine, 2010 5.3 Virus-like particle (VLP) vaccines A virus-like particle (VLP) vaccine produced by the co-expression of the P1 region (VP4, VP2, VP3, and VP1) and viral protease 3CD with recombinant baculovirus was examined for its ability to produce immune responses and...
as higher yields are often associated with increased vaccine availability and reduced production costs. There's still a challenge to achieve high VLP yields for picornaviruses due to the intricate nature of VLP assembly and the limitations of the expression systems used. The cold chain ...
virus-like particle production, ranging fromEscherichia colito mammalian cell lines. The prokaryotic expression system, especiallyEscherichia coli, is the preferred expression host for producing vaccines for global use. Hecolin, the first licensed virus-like particle vaccine derived fromEscherichia coli, ...
effect of a chikungunya virus–like particle vaccine on safety and tolerability outcomes a randomized clinical trial grace l.chen,md, mph 1 ; emily e.coates,phd 1 ; sarah h.plummer,crnp 1 ; et al cristina a.carter,md 1 ; ninaberkowitz,mph 1 ; michelleconan-cibotti,phd 1 ; josephine ...
Engineering virus-like particles as vaccine platforms 下载积分:2000 内容提示: Engineering virus-like particles as vaccine platformsKathryn M Frietze, David S Peabody and Bryce ChackerianVirus-like particles (VLPs) have been utilized as vaccineplatforms to increase the immunogenicity of heterologous...
Virus-like particles (VLPs) are multi-protein structures that mimic the organization and conformation of authentic native viruses but lack the viral genome, potentially yielding safer and cheaper vaccine candidates. Since VLPs resemble a virus, they can present antigens in their native state to elici...
This work describes a novel strategy for the development of a virus-like particle (VLP) based Zika vaccine and shows its effectiveness when tested in a murine model. VLPs are non-infections mimics of the Zika virus, thus chemical inactivation is not required. A VLP vaccine is able to ...
The present invention relates virus-like particle vaccine containing dengue virus recombinant replicon as its core and its preparation method. Such vaccine can efficiently express antigen in the infected tells. Because dengue virus can infect dendritic cells, it can efficiently present antigen and has ...